<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820298</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-481</org_study_id>
    <nct_id>NCT02820298</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of A High-Fat Meal on the Pharmacokinetics of Bexagliflozin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of a high-fat meal on the levels of
      bexagliflozin in the blood in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of Bexagliflozin - Cmax</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Bexagliflozin - Tmax</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose</time_frame>
    <description>Time of maximum observed plasma concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Bexagliflozin - AUC0-t</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from Time 0 to Time t, time of last quantifiable plasma concentration (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Bexagliflozin - AUC0-∞</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from Time 0 to infinity (AUC0-∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Bexagliflozin</measure>
    <time_frame>10 days</time_frame>
    <description>Safety will be assessed based on an analysis of the adverse events record, of laboratory data, including hematology, serum chemistry, urinalysis, urinary electrolytes and creatinine, of electrocardiograms (ECGs), vital signs and physical examinations, and of concomitant medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of Bexagliflozin</measure>
    <time_frame>12 hrs, 24 hrs, 36 hrs, 48 hrs</time_frame>
    <description>urinary glucose excretion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1 - Bexagliflozin with food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.
Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Bexagliflozin without Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin tablet, 20 mg</description>
    <arm_group_label>Group 1 - Bexagliflozin with food</arm_group_label>
    <arm_group_label>Group 2 - Bexagliflozin without Food</arm_group_label>
    <other_name>EGT0001442, EGT0001474</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a Body mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2.

          2. Are willing to use contraception.

          3. Are a non-smokers for at least 3 months prior to screening.

          4. Are willing and able to stay overnight at a clinical research facility as required by
             the protocol.

        Exclusion Criteria:

          1. Women who are nursing or pregnant.

          2. Individuals with a clinically significant history of allergy to drugs or latex.

          3. Have a history of alcohol or drug dependence in the last 12 months.

          4. Have used prescription or over-the-counter (OTC) drugs within 14 days of receiving the
             study drug.

          5. Individuals unable (e.g., food intolerance) or unwilling to consume a high-fat
             breakfast within 25 minutes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Williams, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Denver Clinical Research Unit</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

